Peripheral tissular analysis of rapamycin's effect as a neuroprotective agent in vivo.
Chronic exposure
Histology
Neuroprotective dose
Rapamycin
mTOR
Journal
Naunyn-Schmiedeberg's archives of pharmacology
ISSN: 1432-1912
Titre abrégé: Naunyn Schmiedebergs Arch Pharmacol
Pays: Germany
ID NLM: 0326264
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
03
03
2022
accepted:
15
07
2022
pubmed:
28
7
2022
medline:
15
9
2022
entrez:
27
7
2022
Statut:
ppublish
Résumé
Rapamycin is the best-characterized autophagy inducer, which is related to its antiaging and neuroprotective effects. Although rapamycin is an FDA-approved drug for human use in organ transplantation and cancer therapy, its administration as an antiaging and neuroprotective agent is still controversial because of its immunosuppressive and reported side effects. Therefore, it is critical to determine whether the dose that exerts a neuroprotective effect, 35 times lower than that used as an immunosuppressant agent, harms peripheral organs. We validated the rapamycin neuroprotective dosage in a Parkinson's disease (PD) model induced with paraquat. C57BL/6 J mice were treated with intraperitoneal (IP) rapamycin (1 mg/kg) three times per week, followed by paraquat (10 mg/kg) twice per week for 6 weeks, along with rapamycin on alternate days. Rapamycin significantly decreased dopaminergic neuronal loss induced by paraquat. Since rapamycin's neuroprotective effect in a PD model was observed at 7 weeks of treatment; we evaluated its effect on the liver, kidney, pancreas, and spleen. In addition, we prolonged treatment with rapamycin for 14 weeks. Tissue sections were subjected to histochemical, immunodetection, and morphometric analysis. Chronic rapamycin administration does not affect bodyweight, survival, and liver or kidney morphology. Although the pancreas tissular architecture and cellular distribution in Langerhans islets are modified, they may be reversible. The spleen B lymphocyte and macrophage populations were decreased. Notably, the lymphocyte T population was not affected. Therefore, chronic administration of a rapamycin neuroprotective dose does not produce significant tissular alterations. Our findings support the therapeutic potential of rapamycin as a neuroprotective agent.
Identifiants
pubmed: 35895156
doi: 10.1007/s00210-022-02276-6
pii: 10.1007/s00210-022-02276-6
doi:
Substances chimiques
Immunosuppressive Agents
0
Neuroprotective Agents
0
Paraquat
PLG39H7695
Sirolimus
W36ZG6FT64
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1239-1255Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Antoch MP, Blagosklonny MV (2010) Rapamycin extends maximal lifespan in cancer-prone mice. Am J Pathol 176(5):2092–2097. https://doi.org/10.2353/ajpath.2010.091050
doi: 10.2353/ajpath.2010.091050
pubmed: 20363920
pmcid: 2861075
Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Rosenfeld SV, Blagosklonny MV (2011) Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle 10(24):4230–4236. https://doi.org/10.4161/cc.10.24.18486
doi: 10.4161/cc.10.24.18486
pubmed: 22107964
Arriola Apelo SI, Neuman JC, Baar EL, Syed FA, Cummings NE, Brar HK, Pumper CP, Kimple ME, Lamming DW (2016) Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system. Aging Cell 15(1):28–38. https://doi.org/10.1111/acel.12405
doi: 10.1111/acel.12405
pubmed: 26463117
Barriocanal-Casado E, Hidalgo-Gutiérrez A, Raimundo N, González-García P, Acuña-Castroviejo D, Escames G, López LC (2019) Rapamycin administration is not a valid therapeutic strategy for every case of mitochondrial disease. EBioMedicine 42:511–523. https://doi.org/10.1016/j.ebiom.2019.03.025
doi: 10.1016/j.ebiom.2019.03.025
pubmed: 30898651
pmcid: 6492073
Bartolome A, Guillén C (2014) Role of the mammalian target of rapamycin (mTOR) complexes in pancreatic β-cell mass regulation. Vitam Horm 95:425–469. https://doi.org/10.1016/B978-0-12-800174-5.00017-X
doi: 10.1016/B978-0-12-800174-5.00017-X
pubmed: 24559928
Blagosklonny MV (2011) Rapamycin-induced glucose intolerance: hunger or starvation diabetes. Cell Cycle 10(24):4217–4224. https://doi.org/10.4161/cc.10.24.18595
doi: 10.4161/cc.10.24.18595
pubmed: 22157190
Blagosklonny MV (2019) Rapamycin for longevity: opinion article. Aging (Albany NY) 11(19):8048–8067. https://doi.org/10.18632/aging.102355
doi: 10.18632/aging.102355
Blandino-Rosano M, Barbaresso R, Jimenez-Palomares M, Bozadjieva N, Werneck-de-Castro JP, Hatanaka M, Mirmira RG, Sonenberg N, Liu M, Rüegg MA, Hall MN, Bernal-Mizrachi E (2017) Loss of mTORC1 signalling impairs β-cell homeostasis and insulin processing. Nat Commun 8:16014. https://doi.org/10.1038/ncomms16014
doi: 10.1038/ncomms16014
pubmed: 28699639
pmcid: 5510183
Bravo-San Pedro JM, Senovilla L (2013) Immunostimulatory activity of lifespan-extending agents. Aging (Albany NY) 5(11):793–801. https://doi.org/10.18632/aging.100619
doi: 10.18632/aging.100619
Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM, Claesson K, Stallone G, Russ G, Rostaing L, Kreis H, Burke JT, Brault Y, Scarola JA, Neylan JF (2006) Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 17(2):581–589. https://doi.org/10.1681/ASN.2005090993
doi: 10.1681/ASN.2005090993
pubmed: 16434506
Chong ZZ, Maiese K (2012) Mammalian target of rapamycin signaling in diabetic cardiovascular disease. Cardiovasc Diabetol 11:45. https://doi.org/10.1186/1475-2840-11-45
doi: 10.1186/1475-2840-11-45
pubmed: 22545721
pmcid: 3398846
Chong ZZ, Shang YC, Zhang L, Wang S, Maiese K (2010) Mammalian target of rapamycin: hitting the bull’s-eye for neurological disorders. Oxid Med Cell Longev 3(6):374–391. https://doi.org/10.4161/oxim.3.6.14787
doi: 10.4161/oxim.3.6.14787
pubmed: 21307646
pmcid: 3154047
Chong ZZ, Shang YC, Wang S, Maiese K (2012) Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin. Prog Neurobiol 99(2):128–148. https://doi.org/10.1016/j.pneurobio.2012.08.001
doi: 10.1016/j.pneurobio.2012.08.001
pubmed: 22980037
pmcid: 3479314
Civiletto G, Dogan SA, Cerutti R, Fagiolari G, Moggio M, Lamperti C, Benincá C, Viscomi C, Zeviani M (2018) Rapamycin rescues mitochondrial myopathy via coordinated activation of autophagy and lysosomal biogenesis. EMBO Mol Med 10 (11). https://doi.org/10.15252/emmm.201708799
Comas M, Toshkov I, Kuropatwinski KK, Chernova OB, Polinsky A, Blagosklonny MV, Gudkov AV, Antoch MP (2012) New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-/- mice by delaying carcinogenesis. Aging (Albany NY) 4(10):715–722. https://doi.org/10.18632/aging.100496
doi: 10.18632/aging.100496
Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver P (2007) mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 450(7170):736–740. https://doi.org/10.1038/nature06322
doi: 10.1038/nature06322
pubmed: 18046414
Deblon N, Bourgoin L, Veyrat-Durebex C, Peyrou M, Vinciguerra M, Caillon A, Maeder C, Fournier M, Montet X, Rohner-Jeanrenaud F, Foti M (2012) Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats. Br J Pharmacol 165(7):2325–2340. https://doi.org/10.1111/j.1476-5381.2011.01716.x
doi: 10.1111/j.1476-5381.2011.01716.x
pubmed: 22014210
pmcid: 3413866
Dominguez J, Mahalati K, Kiberd B, McAlister VC, MacDonald AS (2000) Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. Transplantation 70(8):1244–1247. https://doi.org/10.1097/00007890-200010270-00021
doi: 10.1097/00007890-200010270-00021
pubmed: 11063349
Elghazi L, Blandino-Rosano M, Alejandro E, Cras-Méneur C, Bernal-Mizrachi E (2017) Role of nutrients and mTOR signaling in the regulation of pancreatic progenitors development. Mol Metab 6(6):560–573. https://doi.org/10.1016/j.molmet.2017.03.010
doi: 10.1016/j.molmet.2017.03.010
pubmed: 28580286
pmcid: 5444096
Felici R, Buonvicino D, Muzzi M, Cavone L, Guasti D, Lapucci A, Pratesi S, De Cesaris F, Luceri F, Chiarugi A (2017) Post onset, oral rapamycin treatment delays development of mitochondrial encephalopathy only at supramaximal doses. Neuropharmacology 117:74–84. https://doi.org/10.1016/j.neuropharm.2017.01.039
doi: 10.1016/j.neuropharm.2017.01.039
pubmed: 28161373
García-Martínez JM, Alessi DR (2008) mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 416(3):375–385. https://doi.org/10.1042/BJ20081668
doi: 10.1042/BJ20081668
pubmed: 18925875
Goldberg EL, Smithey MJ, Lutes LK, Uhrlaub JL, Nikolich-Žugich J (2014) Immune memory-boosting dose of rapamycin impairs macrophage vesicle acidification and curtails glycolysis in effector CD8 cells, impairing defense against acute infections. J Immunol 193(2):757–763. https://doi.org/10.4049/jimmunol.1400188
doi: 10.4049/jimmunol.1400188
pubmed: 24913978
Graziotto JJ, Cao K, Collins FS, Krainc D (2012) Rapamycin activates autophagy in Hutchinson-Gilford progeria syndrome: implications for normal aging and age-dependent neurodegenerative disorders. Autophagy 8(1):147–151. https://doi.org/10.4161/auto.8.1.18331
doi: 10.4161/auto.8.1.18331
pubmed: 22170152
pmcid: 3336000
Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ, Sabatini DM (2006) Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 11(6):859–871. https://doi.org/10.1016/j.devcel.2006.10.007
doi: 10.1016/j.devcel.2006.10.007
pubmed: 17141160
Gyurus E, Kaposztas Z, Kahan BD (2011) Sirolimus therapy predisposes to new-onset diabetes mellitus after renal transplantation: a long-term analysis of various treatment regimens. Transplant Proc 43(5):1583–1592. https://doi.org/10.1016/j.transproceed.2011.05.001
doi: 10.1016/j.transproceed.2011.05.001
pubmed: 21693238
Heuer M, Dreger NM, Cicinnati VR, Fingas C, Juntermanns B, Paul A, Kaiser GM (2012) Tumor growth effects of rapamycin on human biliary tract cancer cells. Eur J Med Res 17:20. https://doi.org/10.1186/2047-783X-17-20
doi: 10.1186/2047-783X-17-20
pubmed: 22721369
pmcid: 3462134
Houde VP, Brûlé S, Festuccia WT, Blanchard PG, Bellmann K, Deshaies Y, Marette A (2010) Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 59(6):1338–1348. https://doi.org/10.2337/db09-1324
doi: 10.2337/db09-1324
pubmed: 20299475
pmcid: 2874694
Ikenoue T, Inoki K, Yang Q, Zhou X, Guan KL (2008) Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J 27(14):1919–1931. https://doi.org/10.1038/emboj.2008.119
doi: 10.1038/emboj.2008.119
pubmed: 18566587
pmcid: 2486275
Jeon HJ, Lee HE, Yang J (2018) Safety and efficacy of Rapamune® (Sirolimus) in kidney transplant recipients: results of a prospective post-marketing surveillance study in Korea. BMC Nephrol 19(1):201. https://doi.org/10.1186/s12882-018-1002-6
doi: 10.1186/s12882-018-1002-6
pubmed: 30103684
pmcid: 6090799
Jiang J, Zuo Y, Gu Z (2013) Rapamycin protects the mitochondria against oxidative stress and apoptosis in a rat model of Parkinson’s disease. Int J Mol Med 31(4):825–832. https://doi.org/10.3892/ijmm.2013.1280
doi: 10.3892/ijmm.2013.1280
pubmed: 23426728
Johnson SC, Rabinovitch PS, Kaeberlein M (2013) mTOR is a key modulator of ageing and age-related disease. Nature 493(7432):338–345. https://doi.org/10.1038/nature11861
doi: 10.1038/nature11861
pubmed: 23325216
pmcid: 3687363
Johnson SC, Yanos ME, Kayser EB, Quintana A, Sangesland M, Castanza A, Uhde L, Hui J, Wall VZ, Gagnidze A, Oh K, Wasko BM, Ramos FJ, Palmiter RD, Rabinovitch PS, Morgan PG, Sedensky MM, Kaeberlein M (2013) mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome. Science 342(6165):1524–1528. https://doi.org/10.1126/science.1244360
doi: 10.1126/science.1244360
pubmed: 24231806
pmcid: 4055856
Johnson SC, Yanos ME, Bitto A, Castanza A, Gagnidze A, Gonzalez B, Gupta K, Hui J, Jarvie C, Johnson BM, Letexier N, McCanta L, Sangesland M, Tamis O, Uhde L, Van Den Ende A, Rabinovitch PS, Suh Y, Kaeberlein M (2015) Dose-dependent effects of mTOR inhibition on weight and mitochondrial disease in mice. Front Genet 6:247. https://doi.org/10.3389/fgene.2015.00247
doi: 10.3389/fgene.2015.00247
pubmed: 26257774
pmcid: 4510413
Johnston O, Rose CL, Webster AC, Gill JS (2008) Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 19(7):1411–1418. https://doi.org/10.1681/ASN.2007111202
doi: 10.1681/ASN.2007111202
pubmed: 18385422
pmcid: 2440303
Jung CH, Ro SH, Cao J, Otto NM, Kim DH (2010) mTOR regulation of autophagy. FEBS Lett 584(7):1287–1295. https://doi.org/10.1016/j.febslet.2010.01.017
doi: 10.1016/j.febslet.2010.01.017
pubmed: 20083114
pmcid: 2846630
Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier-Kriesche HU, Van Buren CT (1998) Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 66(8):1040–1046. https://doi.org/10.1097/00007890-199810270-00013
doi: 10.1097/00007890-199810270-00013
pubmed: 9808489
Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD (2005) Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80(7):883–889. https://doi.org/10.1097/01.tp.0000184006.43152.8d
doi: 10.1097/01.tp.0000184006.43152.8d
pubmed: 16249734
Khan NA, Nikkanen J, Yatsuga S, Jackson C, Wang L, Pradhan S, Kivelä R, Pessia A, Velagapudi V, Suomalainen A (2017) mTORC1 regulates mitochondrial integrated stress response and mitochondrial myopathy progression. Cell Metab 26(2):419-428.e415. https://doi.org/10.1016/j.cmet.2017.07.007
doi: 10.1016/j.cmet.2017.07.007
pubmed: 28768179
Khanna AK (2000) Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus. Transplantation 70(4):690–694. https://doi.org/10.1097/00007890-200008270-00027
doi: 10.1097/00007890-200008270-00027
pubmed: 10972232
Krebs M, Brunmair B, Brehm A, Artwohl M, Szendroedi J, Nowotny P, Roth E, Fürnsinn C, Promintzer M, Anderwald C, Bischof M, Roden M (2007) The Mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man. Diabetes 56(6):1600–1607. https://doi.org/10.2337/db06-1016
doi: 10.2337/db06-1016
pubmed: 17329620
Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, Davis JG, Salmon AB, Richardson A, Ahima RS, Guertin DA, Sabatini DM, Baur JA (2012) Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335(6076):1638–1643. https://doi.org/10.1126/science.1215135
doi: 10.1126/science.1215135
pubmed: 22461615
pmcid: 3324089
Lamming DW, Ye L, Sabatini DM, Baur JA (2013) Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest 123(3):980–989. https://doi.org/10.1172/JCI64099
doi: 10.1172/JCI64099
pubmed: 23454761
pmcid: 3582126
Lamming DW (2016) Inhibition of the mechanistic target of rapamycin (mTOR)-rapamycin and beyond. Cold Spring Harb Perspect Med 6 (5). https://doi.org/10.1101/cshperspect.a025924
Lebranchu Y (2010) Can we eliminate both calcineurin inhibitors and steroids? Transplant Proc 42(9 Suppl):S25-28. https://doi.org/10.1016/j.transproceed.2010.07.002
doi: 10.1016/j.transproceed.2010.07.002
pubmed: 21095446
Lebwohl D, Anak O, Sahmoud T, Klimovsky J, Elmroth I, Haas T, Posluszny J, Saletan S, Berg W (2013) Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases. Ann N Y Acad Sci 1291:14–32. https://doi.org/10.1111/nyas.12122
doi: 10.1111/nyas.12122
pubmed: 23659703
Leontieva OV, Demidenko ZN, Blagosklonny MV (2014) Rapamycin reverses insulin resistance (IR) in high-glucose medium without causing IR in normoglycemic medium. Cell Death Dis 5:e1214. https://doi.org/10.1038/cddis.2014.178
doi: 10.1038/cddis.2014.178
pubmed: 24810050
pmcid: 4047870
Li S (2009) The possible cellular mechanism for extending lifespan of mice with rapamycin. Biol Proced Online 11:1–2. https://doi.org/10.1007/s12575-009-9015-y
doi: 10.1007/s12575-009-9015-y
pubmed: 19728006
pmcid: 3056009
Li W, Zhang H, Nie A, Ni Q, Li F, Ning G, Li X, Gu Y, Wang Q (2016) mTORC1 pathway mediates beta cell compensatory proliferation in 60 % partial-pancreatectomy mice. Endocrine 53(1):117–128. https://doi.org/10.1007/s12020-016-0861-5
doi: 10.1007/s12020-016-0861-5
pubmed: 26818915
Liu P, Wang Z, Wei W (2014) Phosphorylation of Akt at the C-terminal tail triggers Akt activation. Cell Cycle 13(14):2162–2164. https://doi.org/10.4161/cc.29584
doi: 10.4161/cc.29584
pubmed: 24933731
pmcid: 4111671
Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum CJ, Network DTatIT (2012) Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes 61(9):2340–2348. https://doi.org/10.2337/db12-0049
doi: 10.2337/db12-0049
pubmed: 22721971
pmcid: 3425404
Longo VD, Fontana L (2011) Intermittent supplementation with rapamycin as a dietary restriction mimetic. Aging (Albany NY) 3(11):1039–1040. https://doi.org/10.18632/aging.100401
doi: 10.18632/aging.100401
Malagelada C, Jin ZH, Jackson-Lewis V, Przedborski S, Greene LA (2010) Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson’s disease. J Neurosci 30(3):1166–1175. https://doi.org/10.1523/JNEUROSCI.3944-09.2010
doi: 10.1523/JNEUROSCI.3944-09.2010
pubmed: 20089925
pmcid: 2880868
Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, Lonetto MA, Maecker HT, Kovarik J, Carson S, Glass DJ, Klickstein LB (2014) mTOR inhibition improves immune function in the elderly. Sci Transl Med 6(268):268ra179. https://doi.org/10.1126/scitranslmed.3009892
doi: 10.1126/scitranslmed.3009892
pubmed: 25540326
Mannick JB, Morris M, Hockey HP, Roma G, Beibel M, Kulmatycki K, Watkins M, Shavlakadze T, Zhou W, Quinn D, Glass DJ, Klickstein LB (2018) TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci Transl Med 10 (449). https://doi.org/10.1126/scitranslmed.aaq1564
Mathew T, Kreis H, Friend P (2004) Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 18(4):446–449. https://doi.org/10.1111/j.1399-0012.2004.00188.x
doi: 10.1111/j.1399-0012.2004.00188.x
pubmed: 15233824
McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira-DaSilva AM, Lee HS, Krischer JP, Trapnell BC, Consortium NIoHRLD, Group MT (2011) Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 364(17):1595–1606. https://doi.org/10.1056/NEJMoa1100391
doi: 10.1056/NEJMoa1100391
pubmed: 21410393
pmcid: 3118601
Mendelsohn AR, Larrick JW (2011) Rapamycin as an antiaging therapeutic?: targeting mammalian target of rapamycin to treat Hutchinson-Gilford progeria and neurodegenerative diseases. Rejuvenation Res 14(4):437–441. https://doi.org/10.1089/rej.2011.1238
doi: 10.1089/rej.2011.1238
pubmed: 21851176
Mohacsi PJ, Morris RE (1992) Brief treatment with rapamycin in vivo increases responsiveness to alloantigens measured by the mixed lymphocyte response. Immunol Lett 34(3):273–278. https://doi.org/10.1016/0165-2478(92)90224-c
doi: 10.1016/0165-2478(92)90224-c
pubmed: 1487312
Nair AB, Jacob S (2016) A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 7(2):27–31. https://doi.org/10.4103/0976-0105.177703
doi: 10.4103/0976-0105.177703
pubmed: 27057123
pmcid: 4804402
Noda T, Ohsumi Y (1998) Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. J Biol Chem 273(7):3963–3966. https://doi.org/10.1074/jbc.273.7.3963
doi: 10.1074/jbc.273.7.3963
pubmed: 9461583
Poüs C, Codogno P (2011) Lysosome positioning coordinates mTORC1 activity and autophagy. Nat Cell Biol 13(4):342–344. https://doi.org/10.1038/ncb0411-342
doi: 10.1038/ncb0411-342
pubmed: 21460804
Ramirez-Moreno MJ, Duarte-Jurado AP, Gopar-Cuevas Y, Gonzalez-Alcocer A, Loera-Arias MJ, Saucedo-Cardenas O, Montes de Oca-Luna R, Rodriguez-Rocha H, Garcia-Garcia A (2019) Autophagy stimulation decreases dopaminergic neuronal death mediated by oxidative stress. Mol Neurobiol. https://doi.org/10.1007/s12035-019-01654-1
doi: 10.1007/s12035-019-01654-1
pubmed: 31197654
Rosado C, García-Cosmes P, Fraile P, Vázquez-Sánchez F (2013) Tuberous sclerosis associated with polycystic kidney disease: effects of rapamycin after renal transplantation. Case Rep Transplant 2013:397087. https://doi.org/10.1155/2013/397087
doi: 10.1155/2013/397087
pubmed: 23401839
pmcid: 3562616
Ru W, Peng Y, Zhong L, Tang SJ (2012) A role of the mammalian target of rapamycin (mTOR) in glutamate-induced down-regulation of tuberous sclerosis complex proteins 2 (TSC2). J Mol Neurosci 47(2):340–345. https://doi.org/10.1007/s12031-012-9753-1
doi: 10.1007/s12031-012-9753-1
pubmed: 22492229
Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22(2):159–168. https://doi.org/10.1016/j.molcel.2006.03.029
doi: 10.1016/j.molcel.2006.03.029
pubmed: 16603397
Sarkar S, Krishna G, Imarisio S, Saiki S, O’Kane CJ, Rubinsztein DC (2008) A rational mechanism for combination treatment of Huntington’s disease using lithium and rapamycin. Hum Mol Genet 17(2):170–178. https://doi.org/10.1093/hmg/ddm294
doi: 10.1093/hmg/ddm294
pubmed: 17921520
Saunders RN, Metcalfe MS, Nicholson ML (2001) Rapamycin in transplantation: a review of the evidence. Kidney Int 59(1):3–16. https://doi.org/10.1046/j.1523-1755.2001.00460.x
doi: 10.1046/j.1523-1755.2001.00460.x
pubmed: 11135052
Schreiber KH, Ortiz D, Academia EC, Anies AC, Liao CY, Kennedy BK (2015) Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins. Aging Cell 14(2):265–273. https://doi.org/10.1111/acel.12313
doi: 10.1111/acel.12313
pubmed: 25652038
pmcid: 4364838
Schriever SC, Deutsch MJ, Adamski J, Roscher AA, Ensenauer R (2013) Cellular signaling of amino acids towards mTORC1 activation in impaired human leucine catabolism. J Nutr Biochem 24(5):824–831. https://doi.org/10.1016/j.jnutbio.2012.04.018
doi: 10.1016/j.jnutbio.2012.04.018
pubmed: 22898570
Selman C, Partridge L (2012) A double whammy for aging? Rapamycin extends lifespan and inhibits cancer in inbred female mice. Cell Cycle 11(1):17–18. https://doi.org/10.4161/cc.11.1.18736
doi: 10.4161/cc.11.1.18736
pubmed: 22186783
Siegmund SE, Yang H, Sharma R, Javors M, Skinner O, Mootha V, Hirano M, Schon EA (2017) Low-dose rapamycin extends lifespan in a mouse model of mtDNA depletion syndrome. Hum Mol Genet 26(23):4588–4605. https://doi.org/10.1093/hmg/ddx341
doi: 10.1093/hmg/ddx341
pubmed: 28973153
pmcid: 5886265
Sinagoga KL, Stone WJ, Schiesser JV, Schweitzer JI, Sampson L, Zheng Y, Wells JM (2017) Distinct roles for the mTOR pathway in postnatal morphogenesis, maturation and function of pancreatic islets. Development 144(13):2402–2414. https://doi.org/10.1242/dev.146316
doi: 10.1242/dev.146316
pubmed: 28576773
pmcid: 5536865
Teutonico A, Schena PF, Di Paolo S (2005) Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 16(10):3128–3135. https://doi.org/10.1681/ASN.2005050487
doi: 10.1681/ASN.2005050487
pubmed: 16107580
Tremblay F, Krebs M, Dombrowski L, Brehm A, Bernroider E, Roth E, Nowotny P, Waldhäusl W, Marette A, Roden M (2005) Overactivation of S6 kinase 1 as a cause of human insulin resistance during increased amino acid availability. Diabetes 54(9):2674–2684. https://doi.org/10.2337/diabetes.54.9.2674
doi: 10.2337/diabetes.54.9.2674
pubmed: 16123357
Tsang CK, Qi H, Liu LF, Zheng XF (2007) Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today 12(3–4):112–124. https://doi.org/10.1016/j.drudis.2006.12.008
doi: 10.1016/j.drudis.2006.12.008
pubmed: 17275731
Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH (2007) Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 9(3):316–323. https://doi.org/10.1038/ncb1547
doi: 10.1038/ncb1547
pubmed: 17277771
Volunteers AH (2002) Guidance for industry and reviewers. Center for Biologics Evaluation and Research (CBER)
Wang Y, Liu Y, Lu J, Zhang P, Xu Y, Wang Z, Mao JH, Wei G (2013) Rapamycin inhibits FBXW7 loss-induced epithelial-mesenchymal transition and cancer stem cell-like characteristics in colorectal cancer cells. Biochem Biophys Res Commun 434(2):352–356. https://doi.org/10.1016/j.bbrc.2013.03.077
doi: 10.1016/j.bbrc.2013.03.077
pubmed: 23558291
pmcid: 3646979
Wataya-Kaneda M, Tanaka M, Nakamura A, Matsumoto S, Katayama I (2012) A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex. Arch Dermatol 148(1):138–139. https://doi.org/10.1001/archderm.148.1.138
doi: 10.1001/archderm.148.1.138
pubmed: 22250258
Wicker LS, Boltz RC, Matt V, Nichols EA, Peterson LB, Sigal NH (1990) Suppression of B cell activation by cyclosporin A, FK506 and rapamycin. Eur J Immunol 20(10):2277–2283. https://doi.org/10.1002/eji.1830201017
doi: 10.1002/eji.1830201017
pubmed: 1700753
Xie J, Herbert TP (2012) The role of mammalian target of rapamycin (mTOR) in the regulation of pancreatic β-cell mass: implications in the development of type-2 diabetes. Cell Mol Life Sci 69(8):1289–1304. https://doi.org/10.1007/s00018-011-0874-4
doi: 10.1007/s00018-011-0874-4
pubmed: 22068611